The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Chemotherapy with erlotinib or chemotherapy alone in advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors (TKI).
Sarah B. Goldberg
No relevant relationships to disclose
Geoffrey R. Oxnard
Consultant or Advisory Role - Genentech
Subba Digumarthy
No relevant relationships to disclose
Alona Muzikansky
No relevant relationships to disclose
David Michael Jackman
Consultant or Advisory Role - Foundation Medicine; Genentech
Inga Tolin Lennes
No relevant relationships to disclose
Lecia V. Sequist
Consultant or Advisory Role - Celgene; Clovis Oncology; Daiichi Sankyo (U); GlaxoSmithKline; Merrimack (U)